

Palliative integrated oncology advanced EPEC-Oncology course, Cairo, Egypt, April 2009.
Basic principles of genetics, pathology, cytology, tissue culture, surgical oncology, radiotherapy and statistics.
2007-2008

Seminars and presentations:

- *Castrate Resistant Prostate case presentation.* . Emad Shash, MD. Ermatingen, Switzerland, March 2010. 9th ESO-ESMO Master class.
- *Von-Hippel-Lindau Syndrome case presentation.* Emad Shash, MD. Amman, Jordan, October 2009. EASO Urogenital Course.
- *Morbidity and mortality case presentations* every 3 month regularly as part of the residents program at the Medical oncology department (over the past 3 years)
- *Active Participation in the clinical grand round at NCI, Cairo, Egypt and giving seminar presentations on different topics.*

EDITORIALS & PUBLICATIONS:

- Metastatic Colorectal Cancer: Are we talking about curability?** Mohamed Abdulla and Emad Shash. *Advances in Oncology*; March 2010; vol. 5: issue 1: 1-4
- Ongoing original article about Bone Lymphoma (New Categorization of Egyptian Bone Lymphoma patients: Single Institutional study)
- **GIST: The past, the present and the future** (review article submitted and will be published in September 2010)

RESEARCH ACTIVITIES:

Participation in ongoing phase II & III global clinical trials in the field of both solid and hematology malignancies, in addition to participation of local investigator initiated clinical research projects.

- **MERITS study by Egyptian Foundation For Cancer Research:** Multi-Center, Middle East, Phase-II Study, Non-Comparative, of the RAF-Kinase Inhibitor Sorafenib in Patients with Advanced Renal Cell Carcinoma to Evaluate the Efficacy and Tolerability of the Drug (**Sub-Investigator**)
- **NSABP B-44-I, CIRG (TRIO) 011, Roche BO20906, BETH:** A Multicenter Phase III Randomized Trial of Adjuvant Therapy for Patients with HER2-Positive Node-Positive or High Risk Node-Negative Breast Cancer Comparing Chemotherapy Plus Trastuzumab with Chemotherapy Plus Trastuzumab Plus Bevacizumab (**Sub-Investigator**)
- **CRAD001Y2301, Novartis:** A Randomized Double-Blind, Placebo-Controlled Study of Everolimus in Combination with Exemestane in the Treatment of Postmenopausal Women with Estrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer Who Are Refractory to Letrozole or Anastrozole (**Coordinator**)
- **CRAD001L2201, Novartis:** A randomized, open label, multi-center phase II study to compare bevacizumab plus RAD001 versus interferon alfa- 2a plus bevacizumab for the first-line treatment of patients with metastatic clear cell carcinoma of the kidney (**Sub-Investigator**)
- **M10-963:** An Open-label, Randomized Phase 3 Study of the Efficacy and Tolerability of Linifanib (ABT-869) versus Sorafenib in Subjects with Advanced Hepatocellular Carcinoma (HCC)(**Sub-Investigator**)

LANGUAGES: English (fluent), Arabic (mother tongue) & French (moderate level).

REFERENCES:

To be listed upon request